Dr. Paul Schellhammer
Dr. Paul Schellhammer received his undergraduate education at the University of Notre Dame and his medical school training and Cornell Medical College in New York City. His surgical and urologic training were taken at the University Hospital of Cleveland in Cleveland, Ohio and the Medical College of Virginia, Richmond, Virginia. This was followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Subsequently he joined the practice of Devine Poutasse Fiveash Urology and became a faculty member of Eastern Virginia Medical School where he eventually achieved the rank of Professor and then also served as Chairman of the Department of Urology and Program Director of the Resident Training Program.
Dr. Schellhammer has served as a medical officer in Vietnam, as a trustee of the American Board of Urology and as its President. He has also served as President of the Society of Urologic Oncology, as President of his Mid-Atlantic Section of the American Urologic Association, as a member of the Board of Directors of the American Urologic Association, and President of the American Urologic Association 2007-2008.
Dr. Matthew Davenport
Matthew Davenport MD MBA FSAR FSABI FACR is the William Martel Professor of Radiology and Professor of Urology, and Service Chief and Vice Chair in the Department of Radiology at Michigan Medicine. He is an internationally recognized expert on renal mass imaging and the safety and efficacy of radiographic contrast material. He has served on the U.S. Food and Drug Administration Medical Imaging Drugs Advisory Committee, as Chair of the American College of Radiology’s (ACR) Committee on Drugs and Contrast Media, as Vice Chair of the ACR Quality and Safety Commission, and as Chair of the Renal Cell Carcinoma Disease-Focused Panel for the Society of Abdominal Radiology (SAR).
He Co-Chairs the Oversight Committee of multicenter research groups working within the SAR and founded and Chairs the Radiology and Data System (RADS) Steering Committee for the ACR. He is a co-author on national policy statements, has published over 250 manuscripts, is frequently interviewed regarding important issues in Radiology (WSJ, NYT, NBC, Fortune, Forbes, etc), founded the Michigan Radiology Quality Collaborative, and co-directs the Weiser Center for Prostate Cancer. His primary clinical interests include high-value care and urologic imaging.
Dr. John Groth
Dr. John Groth is not only a pathologist who routinely assesses prostate tissue but also a patient with prostate cancer. He was diagnosed with prostate acinar adenocarcinoma Gleason 3+3=6 (grade group 1), with 4 cores, the largest focus 6 mm (30% of the core) in March of 2024. He also had his tissue analyzed by ArteraAI Prostate, the first FDA-approved multimodal Artificial Intelligence pathology test, which placed him in the 52nd percentile for prognostic risk for his given NCCN risk group. Dr. Groth is currently under active surveillance for prostate cancer.
As a pathologist and physician informaticist at Endeavor Health, Dr. Groth specializes in anatomic and clinical pathology and informatics, focusing on diagnostic precision, innovation, and patient-centered care. He integrates advanced technology, informatics, and collaborative practices to support accurate diagnoses that drive effective patient care. Dr. Groth is currently leading efforts for patient-centered pathology reports and pathology clinics to help patients better understand their diagnosis.
Passionate about mentoring, Dr. Groth guides medical students, residents, and fellows, fostering the next generation of leaders in pathology and informatics. He is the co-chair for the Digital Pathology Association’s Regulatory & Standards Task Force, co-founder of the Global Pathology Interoperability Alliance, and a member of the American Society of Clinical Pathology’s Patient Champions Committee. Additionally, Dr. Groth serves as the vice president of the Illinois Society of Cytotechnology and as the treasurer of the Chicago Pathology Society. He resides in Illinois with his wonderful wife and two daughters.
Dr. Francis V. James
Dr. Francis V. James is a radiation oncologist in India with extensive experience in urological cancers, including prostate cancer. He is Professor of Radiation Oncology at Sree Mookambika Cancer Centre in Tamil Nadu and previously served as Professor and Head of Radiation Oncology at the Regional Cancer Centre in Trivandrum from 2015 to 2025.
Dr. James earned his MBBS and MD from the University of Kerala and completed international fellowships at the University of Leeds and at the Institute of Cancer Research / Royal Marsden Hospital in the United Kingdom. Over the course of his career, he has published on prostate cancer and other urological malignancies and has been active in leading professional organizations in radiation oncology. He is a Fellow of the Indian College of Radiation Oncology and a member of ESMO, ASCO, and the Association of Radiation Oncologists of India.
Alexandra Scholz
Alexandra Scholz serves as CEO of the Prostate Cancer Research Institute (PCRI), a not-for-profit organization dedicated to helping prostate cancer patients and their families research their treatment options. In 2010, she began her prostate cancer training and worked as a public relations consultant for PCRI. In 2013, she began working in public relations and patient education for Prostate Oncology Specialists, a private clinic dedicated to expert prostate cancer treatments through medical oncology. Due to her training and passion for patients, she transitioned back to the PCRI, where she currently leads a team dedicated to providing reliable, unbiased prostate cancer information to patients and caregivers worldwide. She serves on multiple prostate cancer advisory boards, leadership boards and is a strong advocate for patient education.
